- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02666768
ACTIMMUNE in Intermediate Osteopetrosis
Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis
Study Overview
Detailed Description
Osteopetrosis is a rare inherited metabolic bone disease characterized by impaired osteoclast function resulting in defective bone resorption and generalized high bone mass and mineral density (BMD). In patients with severe disease, this high bone mass compromises bone marrow space leading to marrow failure and frequent infections, along with hepatosplenomegaly from extramedullary hematopoiesis. Currently, the only treatment for individuals with severe forms of osteopetrosis is hematopoietic cell transplantation (HCT), however survival in patients with osteopetrosis treated with HCT is only around 55%. Therefore, this treatment is only indicated in select individuals with life-threatening complications of their disease. Thus additional treatments for osteopetrosis are needed both for individuals who are not candidates for HCT and to prolong the time until HCT is needed.
Interferon gamma (IFN-γ) is a naturally occurring cytokine that has been shown to have anti-microbial and anti-viral immunomodulatory effects, and is a potent stimulator of superoxide anion production which in turn promotes the formation and activation of osteoclasts. Two previous studies of IFN-γ1b in a small group of individuals with osteopetrosis found a decrease in trabecular bone area, an increase in marrow space, a decrease in the number of severe infections requiring antibiotic therapy, and an increase in superoxide generation by granulocyte-macrophage colonies.
Therefore, the investigators will conduct an early phase 2, multi-center, open-label, 12-month clinical trial of ACTIMMUNE (IFN-γ1b) treatment of patients with intermediate osteopetrosis to determine the following:
- The feasibility and tolerability of interferon gamma-1b treatment for 1 year in patients with intermediate osteopetrosis. Specifically, i) the ability to enroll patients, and ii) continued treatment throughout the 1-year observational period.
- Change in immunologic and hematologic function, bone mineral density and osteoclast function, physical function and quality of life.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Torrance, California, United States, 90502
- Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55454
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of osteopetrosis; and
- Anemia (Hemoglobin <12 g/dL) not related to iron deficiency, or
- Neutropenia (Neutrophil count <1000 neutrophils/ul unsupported with cytokines), or
- Thrombocytopenia (Platelet count <50,000 cells x 109/L), or
- History of impaired bone healing, or
- ≥ 1 serious infection over prior year defined as requiring hospitalization and/or IV antibiotics, and
- Age > 1 year; and
- Ability to travel to a study center for every 3-6 month study visits; and
- Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided.
Exclusion Criteria:
- 12 months or fewer following HCT;
- Pregnancy or breastfeeding;
- Known or suspected allergy to interferon gamma-1b or related products;
- Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment;
- ALT greater than 3 fold higher than normal; or
- Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: gamma interferon-1b
Gamma interferon-1b 100 mcg subcutaneous (SC) 3 times weekly for 12 months
|
gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Related Adverse Events CTCAE v4.0 Grade 3 or Higher
Time Frame: 12 months
|
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 defines a Grade 4 event as having life-threatening consequences, and/or urgent intervention indicated.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Bone Mineral Density (BMD)
Time Frame: 6 months
|
BMD measured by peripheral quantitative computed tomography (pQCT) in bone area w/ BMD<169mg/m3
|
6 months
|
Change From Baseline in White Blood Cell Count (WBC)
Time Frame: 6 months
|
6 months
|
|
Change From Baseline in Pain
Time Frame: 6 months
|
Survey name: RAND 36-Item Health Survey (Version 1.0) Scale name: Pain Scale range: 0-100; Higher score means less pain
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lynda E Polgreen, MD, MS, Los Angeles BioMedical Research Center at Harbor-UCLA
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21549-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteopetrosis
-
Indiana UniversityHorizon Pharma Ireland, Ltd., Dublin IrelandCompleted
-
Masonic Cancer Center, University of MinnesotaCompleted
-
Rocket Pharmaceuticals Inc.California Institute for Regenerative Medicine (CIRM)TerminatedInfantile Malignant OsteopetrosisUnited States
-
Odense University HospitalCompleted
-
InterMuneCompletedOsteopetrosisUnited States
-
Tehran University of Medical SciencesUnknownOsteopetrosisIran, Islamic Republic of
-
University of ChicagoTerminated
-
Masonic Cancer Center, University of MinnesotaTerminated
-
St. Jude Children's Research HospitalTerminated
-
FDA Office of Orphan Products DevelopmentMedical University of South CarolinaCompleted
Clinical Trials on Interferon gamma-1b
-
Nantes University HospitalActive, not recruiting
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
Children's Hospital of PhiladelphiaFriedreich's Ataxia Research Alliance; Vidara Therapeutics Research LtdCompleted
-
InterMuneTerminated
-
InterMuneTerminatedPeritoneal Carcinoma | Ovarian CarcinomaUnited States
-
InterMuneCompletedPulmonary Fibrosis | Lung DiseaseUnited States
-
InterMuneCompletedCystic FibrosisUnited States
-
InterMuneCompleted
-
AmgenCompleted
-
InterMuneTerminatedIdiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung DiseaseUnited States